AlphaTON Capital (ATON) Registration Filing summary

Company overview and business model

• Clinical-stage immuno-oncology company focused on developing first-in-class therapies targeting checkpoint resistance pathways to improve cancer treatment outcomes.

• Recent strategic shift includes pausing or discontinuing certain clinical programs due to funding constraints and seeking external financing for key subsidiaries.

• Exploring strategic alternatives such as asset sales, partnerships, mergers, or restructuring.

• Operates as a British Virgin Islands business company, listed on Nasdaq since 2021.

Financial performance and metrics

• Reported net loss attributable to owners of $(75.3) million for the year ended March 31, 2024, compared to $(104.6) million in the prior year.

• Shareholders' equity was $695,000 as of September 30, 2024, below the Nasdaq minimum requirement of $2.5 million.

• Completed a $2.15 million private placement in January 2025 to address Nasdaq compliance.

Use of proceeds and capital allocation

• Proceeds from offerings will be used for general corporate purposes, working capital, debt repayment, R&D, potential acquisitions, and strategic alternatives including possible sale or restructuring.

• Management has broad discretion over allocation of funds, with no specific amounts or timing determined.